Search details
1.
Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Neoplasma
; 69(6): 1466-1473, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36591807
2.
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
Hematol Oncol
; 36(5): 773-778, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30129045
3.
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Hematol Oncol
; 36(1): 110-115, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29083050
4.
Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.
Am J Hematol
; 94(2): E50-E53, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30474171
5.
Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.
Cancers (Basel)
; 12(8)2020 Jul 31.
Article
in English
| MEDLINE | ID: mdl-32751805
6.
The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group.
Leuk Res
; 73: 29-38, 2018 10.
Article
in English
| MEDLINE | ID: mdl-30195062
7.
Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.
Bone Marrow Transplant
; 56(3): 709-712, 2021 03.
Article
in English
| MEDLINE | ID: mdl-32884117
Results
1 -
7
de 7
1
Next >
>>